---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-23-000029"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T18:31:57.336677+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance

## Summary
- Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.
- GAAP diluted EPS $1.73 vs $1.42 YoY; non-GAAP diluted EPS $2.29 vs $1.90.
- Biktarvy sales grew 12% to $3.1B; Oncology sales up 33% to $769M.
- Full-year product sales guidance raised to $26.7-26.9B; non-GAAP EPS raised to $6.65-6.85.
- Veklury sales fell 31% to $636M; R&D expenses rose to $1.5B on clinical activity and magrolimab discontinuations.

## SEC filing metadata
- accession: 0000882095-23-000029
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/0000882095-23-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/gild-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-23-000029
- JSON: https://secwatch.observer/filing/0000882095-23-000029.json
- Plain text: https://secwatch.observer/filing/0000882095-23-000029.txt

## Key facts
- Earnings Releases
  GILEAD SCIENCES, INC. reported the third quarter of 2023 results: revenue $7.1 billion, EPS $1.73.
  - Period: the third quarter of 2023
  - Revenue: $7.1 billion
  - EPS: $1.73
  - Result: reported results
  source text: Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/0000882095-23-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.